ACADIA PHARMACEUTICALS INC. Other Comprehensive Income (Loss), Net of Tax
ACADIA PHARMACEUTICALS INC. (ACAD) reported Other Comprehensive Income (Loss), Net of Tax of $1.15 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2021-12-31 was -$191.00K.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2021-09-30 was -$39.00K.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2021-06-30 was $4.00K.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2021-03-31 was -$2.00K, a 100.16% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2025 was $1.15M, a 330.22% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2024 was $268.00K, a 73.17% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2023 was $999.00K.
- ACADIA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$783.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.15M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $268.00K 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $999.00K 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$783.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$230.00K derived: sum of 2 quarters · filed 2024-02-28 | -$226.00K derived: sum of 3 quarters · filed 2024-02-28 | -$228.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | -$39.00K 10-Q · filed 2021-11-09 | -$35.00K derived: sum of 2 quarters · filed 2021-11-09 | -$37.00K 10-Q · filed 2021-11-09 | -$510.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $4.00K 10-Q · filed 2021-08-05 | $2.00K 10-Q · filed 2021-08-05 | -$471.00K derived: sum of 3 quarters · filed 2023-02-28 | -$1.44M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$2.00K 10-Q · filed 2021-05-06 | -$475.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.45M derived: sum of 3 quarters · filed 2023-02-28 | -$1.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.44M derived: sum of 2 quarters · filed 2023-02-28 | -$1.49M derived: sum of 3 quarters · filed 2023-02-28 | -$261.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$971.00K 10-Q · filed 2021-11-09 | -$1.02M derived: sum of 2 quarters · filed 2021-11-09 | $212.00K 10-Q · filed 2021-11-09 | $89.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$45.00K 10-Q · filed 2021-08-05 | $1.18M 10-Q · filed 2021-08-05 | $1.06M derived: sum of 3 quarters · filed 2022-03-01 | $926.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.23M 10-Q · filed 2021-05-06 | $1.10M derived: sum of 2 quarters · filed 2022-03-01 | $971.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.32M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$257.00K derived: sum of 2 quarters · filed 2022-03-01 | $90.00K derived: sum of 3 quarters · filed 2022-03-01 | $669.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | -$134.00K 10-Q · filed 2020-11-04 | $213.00K derived: sum of 2 quarters · filed 2020-11-04 | $792.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $347.00K 10-Q · filed 2020-08-06 | $926.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $579.00K 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $27.00K 10-K · filed 2021-02-25 | |||
| 2017-12-31 | -$505.00K 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $95.00K 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $20.00K 10-K · filed 2018-02-27 | |||
| 2014-12-31 | -$57.00K 10-K · filed 2017-02-28 | |||
| 2013-12-31 | $44.00K 10-K · filed 2016-02-29 | |||
| 2012-12-31 | -$5.00K 10-K · filed 2015-02-26 | |||
| 2011-12-31 | -$503.00K 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $29.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |